Preventing Epstein-Barr Virus Lymphoproliferative Disease After Bone Marrow Transplantation

Journal of Immunotherapy

Volumn 24, Issue 4, 2001, Pages 283-284

  Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

ALLOIMMUNITY; BONE MARROW TRANSPLANTATION; CELL CULTURE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DISEASE PREDISPOSITION; DRUG EFFICACY; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MARKER GENE; NOTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

ADOPTIVE TRANSFER; ANTIGENS, VIRAL; BONE MARROW TRANSPLANTATION; CELL LINE; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0034852780     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200107000-00002     Document Type: Editorial

References (18)

1. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185-91.
2. Rooney CM, Smith CA, Ng C, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345: 9-13.
3. Heslop HE, Ng CYC, Li C, et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996; 2: 551-5.
4. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.
5. Heslop HE, Brenner MK, Rooney CM. Donor T cells to treat EBV-associated lymphoma. N Engl J Med 1994; 331: 679-80.
6. Lucas KG, Burton RL, Zimmerman SE, et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998; 91: 3654-61.
7. Bollard CM, Rooney CM, Huls MH, et al. Long term follow-up of patients who received EBV specific CTLs for the prevention or treatment of EBV lymphoma. Blood 2000;96:478a (abstract).
8. Gustafsson A, Levitsky V, Zou JZ, et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807-14.
9. Musk P, Szamania S, Galloway A, et al. Epstein-Barr virus-specific cytotoxic T cells for prevention of Epstein-Barr virus-induced lymphoma in haploidentical allogeneic stem cell transplantation. J Immunother 2001; 24: 312-322.
10. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-31.
11. Koehne G, Gallardo HF, Sadelain M, O'Reilly RJ. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000; 96: 109-17.
12. Gottschalk S, Ng CYC, Smith CA, et al. An Epstein-Barr virus deletion mutant that causes fatal lymphoproliferative disease unresponsive to virus-specific T cell therapy. Blood 2001; 97: 835-43.
13. Sun Q, Pollok KE, Burton RL, et al. Simultaneous ex vivo expansion of cytomegalovirus and Epstein-Barr virus-specific cytotoxic T lymphocytes using B-lymphoblastoid cell lines expressing cytomegalovirus pp65. Blood 1999; 94: 3242-50.
14. Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. Bone Marrow Transplant 2001; 27: 53-64.
15. Montagna D, Yvon E, Calcaterra V, et al. Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. Blood 1999; 93: 3550-7.
16. Aguilar LK, Rooney CM, Heslop HE. Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation. Curr Opin Oncol 1999; 11: 96-101.
17. Hale G, Waldmann H, for CAMPATH Users. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood 1998;91:3079-83.
18. Cavazzana-Calvo M, Bensoussan D, Jabado N, et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol 1998; 103: 543-51.